<?xml version='1.0' encoding='utf-8'?>
<document id="17455113"><sentence text="Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans."><entity charOffset="57-68" id="DDI-PubMed.17455113.s1.e0" text="pravastatin" /><entity charOffset="82-93" id="DDI-PubMed.17455113.s1.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.17455113.s1.e0" e2="DDI-PubMed.17455113.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17455113.s1.e0" e2="DDI-PubMed.17455113.s1.e1" /></sentence><sentence text="Coadministration of gemfibrozil (600 mg, b"><entity charOffset="20-31" id="DDI-PubMed.17455113.s2.e0" text="gemfibrozil" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=", 3 days) with pravastatin (40 mg/day) decreased the renal clearance of pravastatin by approximately 40% in healthy volunteers"><entity charOffset="15-26" id="DDI-PubMed.17455113.s5.e0" text="pravastatin" /><entity charOffset="72-83" id="DDI-PubMed.17455113.s5.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.17455113.s5.e0" e2="DDI-PubMed.17455113.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17455113.s5.e0" e2="DDI-PubMed.17455113.s5.e1" /></sentence><sentence text=" To investigate the mechanism of this drug-drug interaction in the renal excretion process, we undertook an uptake study of pravastatin using human organic anion transporters (hOATs)-expressing S2 cells"><entity charOffset="124-135" id="DDI-PubMed.17455113.s6.e0" text="pravastatin" /></sentence><sentence text=" hOAT3 and hOAT4 transported pravastatin in a saturatable manner with Michaelis--Menten constants of 27"><entity charOffset="29-40" id="DDI-PubMed.17455113.s7.e0" text="pravastatin" /></sentence><sentence text="7 microM and 257 microM respectively" /><sentence text=" On the other hand, hOAT1 and hOAT2 did not transport pravastatin"><entity charOffset="54-65" id="DDI-PubMed.17455113.s9.e0" text="pravastatin" /></sentence><sentence text=" Gemfibrozil and its glucuronide and carboxylic metabolite forms inhibited the uptake of pravastatin by hOAT3 with IC(50) values of 6"><entity charOffset="1-12" id="DDI-PubMed.17455113.s10.e0" text="Gemfibrozil" /><entity charOffset="21-32" id="DDI-PubMed.17455113.s10.e1" text="glucuronide" /><entity charOffset="37-47" id="DDI-PubMed.17455113.s10.e2" text="carboxylic" /><entity charOffset="89-100" id="DDI-PubMed.17455113.s10.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e0" e2="DDI-PubMed.17455113.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e0" e2="DDI-PubMed.17455113.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e0" e2="DDI-PubMed.17455113.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e0" e2="DDI-PubMed.17455113.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e1" e2="DDI-PubMed.17455113.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e1" e2="DDI-PubMed.17455113.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e1" e2="DDI-PubMed.17455113.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e2" e2="DDI-PubMed.17455113.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s10.e2" e2="DDI-PubMed.17455113.s10.e3" /></sentence><sentence text="8 microM, 19" /><sentence text="7 microM and 5" /><sentence text="4 microM, respectively" /><sentence text=" Considering the plasma concentrations of gemfibrozil and its metabolites in humans, the inhibition of hOAT3-mediated pravastatin transport by gemfibrozil and its metabolites would lead to a decrease in the renal clearance of pravastatin in clinical settings"><entity charOffset="42-53" id="DDI-PubMed.17455113.s14.e0" text="gemfibrozil" /><entity charOffset="118-129" id="DDI-PubMed.17455113.s14.e1" text="pravastatin" /><entity charOffset="143-154" id="DDI-PubMed.17455113.s14.e2" text="gemfibrozil" /><entity charOffset="226-237" id="DDI-PubMed.17455113.s14.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e0" e2="DDI-PubMed.17455113.s14.e0" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e0" e2="DDI-PubMed.17455113.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e0" e2="DDI-PubMed.17455113.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e0" e2="DDI-PubMed.17455113.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e1" e2="DDI-PubMed.17455113.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e1" e2="DDI-PubMed.17455113.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e1" e2="DDI-PubMed.17455113.s14.e3" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e2" e2="DDI-PubMed.17455113.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17455113.s14.e2" e2="DDI-PubMed.17455113.s14.e3" /></sentence><sentence text="" /></document>